Prothrombotic risk of vitamin K antagonists during the first days of treatment: One more reason to use new oral anticoagulants

Int J Cardiol. 2015:186:141-2. doi: 10.1016/j.ijcard.2015.03.234. Epub 2015 Mar 18.

Authors

Sébastien Gaertner¹, Elena-Mihaela Cordeanu², Corina Mirea², Dominique Stephan²

Affiliations

¹ Department of Vascular Medicine and Clinical Pharmacology, Strasbourg University Hospital, France. Electronic address: sebastien.gaertner@chru-strasbourg.fr.
² Department of Vascular Medicine and Clinical Pharmacology, Strasbourg University Hospital, France.

PMID: 25818758
DOI: 10.1016/j.ijcard.2015.03.234

No abstract available

Keywords: Atrial fibrillation; Hypercoagulable state; Stroke; Vitamin K antagonist.

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Anticoagulants / adverse effects*
Atrial Fibrillation / drug therapy*
Electrocardiography
Factor Xa Inhibitors / therapeutic use
Female
Humans
Phenindione / adverse effects
Phenindione / analogs & derivatives*
Rivaroxaban / therapeutic use
Thrombosis / chemically induced*
Thrombosis / drug therapy
Vitamin K / antagonists & inhibitors*

Substances

Anticoagulants
Factor Xa Inhibitors
Vitamin K
Phenindione
Rivaroxaban
fluindione